A new paradigm for gene therapy
Interviewee/Contributor
Peter Marks
Organisation
US Food and Drug Administration
Policy & Regulation
Addressing the challenges of gene therapy medicinal products
Interviewee/Contributor
Paula Salmikangas and Björn Carlsson
Organisation
NDA Group
EU medicine approvals with public health impact
Interviewee/Contributor
Jane Morrison
Organisation
MedNous
Drug development robust, despite the pandemic
Interviewee/Contributor
Bruno Pagliara
Organisation
MedNous
Real world evidence is changing regulatory policy
Interviewee/Contributor
Marie Manley and Zina Chatzidimitriadou
Organisation
Sidley Austin LLP
Integrated product development for ATMPs
Interviewee/Contributor
Claes Buxfeldt and Paula Salmikangas
Organisation
NDA Advisory Services Ltd
Establishing a new role for real world evidence
Interviewee/Contributor
Tara Raveendran
Organisation
Shore Capital Ltd
Improving cardiac safety testing protocols
Interviewee/Contributor
John Ridley
Organisation
Metrion Biosciences Ltd
What patients really want: involvement
Interviewee/Contributor
Pierre Meulien
Organisation
Innovative Medicines Initiative
Scientists and industry mobilise against coronavirus
Interviewee/Contributor
Victoria English
Organisation
MedNous